Data compiled by Redley Lamar · ChainSifter Intelligence
13Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
IDEAYA Biosciences, Inc. (IDYA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
25Total relationships
5Distinct source URLs
14High confidence
0.809Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN grap…
under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross proceeds of …
BIOCYTOGEN-PHARMACEUTICALS-CO-LTD
BIOCYTOGEN-PHARMACEUTICALS-CO-LTD
90%
timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Option and License Agreement with Biocytogen Pharmaceut…
JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD
JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD
90%
timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the License Agreement with Jiangsu Hengrui Pharmaceuticals …
NVS
Novartis AG
90%
Reciprocal relationship from NVS graph: Reciprocal relationship from IDYA graph: timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license…
NVS
Novartis AG
90%
timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the License Agreement with Novartis
UNIVERSITY-OF-MANCHESTER
UNIVERSITY-OF-MANCHESTER
90%
timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Option and License Agreement with CRT and University of…
mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctuate significantly, which wil…
Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: mbined with expected future losses,…
IDEAYA Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
SERVIER
SERVIER
90%
The Company has financed its operations primarily through the sale and issuance of common stock, the upfront payment and certain milestone payments received from GSK (as defined below) and the upfron…
Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: to each performance obligation by the amount that the entity expects to receive for transferring the goods or services…
to each performance obligation by the amount that the entity expects to receive for transferring the goods or services. Since evidence based on observable prices is not available for the performance …
mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctuate significantly, which wil…
Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit…
BIOCYTOGEN-PHARMACEUTICALS-CO-LTD
BIOCYTOGEN-PHARMACEUTICALS-CO-LTD
62%
eriods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctu…
FOR-IDE397-SERVIER-PHARMACEUTICALS-LLC
FOR-IDE397-SERVIER-PHARMACEUTICALS-LLC
62%
uthority disagreeing as to the design or implementation of our clinical trials; • delays in obtaining regulatory authorization to commence a clinical trial; • reaching agreement on acceptable terms w…
JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD
JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD
62%
eriods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctu…
IDEAYA Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IDYA-DEBT
Debt stack $28.6M
90%
Market cache reports total debt of $28.6M.
IDYA-DEBT-10192
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-12-31.
IDYA-DEBT-10191
Warrants outstanding: 285715
90%
xbrl warrant detail from xbrl 2024-12-31.
IDEAYA Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for IDEAYA Biosciences, Inc..
IDEAYA Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
IDYA-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 260 tracked holders.
IDEAYA Biosciences, Inc. Extended Supply Chain Network
